Last $38.89 USD
Change Today +0.02 / 0.05%
Volume 105.4K
MYGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 10:57 AM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

myriad genetics inc (MYGN) Snapshot

Open
$38.83
Previous Close
$38.87
Day High
$39.05
Day Low
$38.44
52 Week High
05/1/14 - $42.50
52 Week Low
12/30/13 - $20.02
Market Cap
2.8B
Average Volume 10 Days
641.0K
EPS TTM
$2.30
Shares Outstanding
72.8M
EX-Date
--
P/E TM
16.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for MYRIAD GENETICS INC (MYGN)

myriad genetics inc (MYGN) Related Businessweek News

View More BusinessWeek News

myriad genetics inc (MYGN) Details

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive, personalized, and prognostic medicine tests in the United States and internationally. The company operates through three segments: Research, Molecular Diagnostics, and Pharmaceutical and Clinical Services. The company’s molecular diagnostic tests are designed to analyze genes; diagnose diseases, expression levels, and proteins to assess an individual’s risk for developing disease later in life; determine a patient’s likelihood of responding to a particular drug; and assess a patient’s risk of disease progression and disease recurrence. It offers various molecular diagnostic tests, including BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; EndoPredict medicine test for breast cancer; and MELARIS predictive medicine test for hereditary melanoma. The company also provides myPath Melanoma diagnostic medicine test for melanoma; myPlan lung cancer, a prognostic medicine test for lung cancer; myRisk Hereditary Cancer, a predictive medicine test for hereditary cancer; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and Vectra DA, a personalized medicine test for rheumatoid arthritis. In addition, it offers biomarker discovery, and pharmaceutical and clinical services to pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

1,649 Employees
Last Reported Date: 08/13/14
Founded in 1991

myriad genetics inc (MYGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $956.9K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $786.9K
President of Myriad Genetic Laboratories Inc
Total Annual Compensation: $1.1M
Executive Vice President, General Counsel and...
Total Annual Compensation: $716.9K
Chief Scientific Officer
Total Annual Compensation: $702.9K
Compensation as of Fiscal Year 2013.

myriad genetics inc (MYGN) Key Developments

Myriad Presents Tumor BRACAnalysis CDx(TM) Study at ESMO

Myriad Genetics Inc. announced that its Tumor BRACAnalysis CDx(TM) companion diagnostic test significantly improved the detection of cancer-causing BRCA 1/2 mutations by 44% in women with ovarian cancer. Data from this new study were presented at the 2014 European Society for Medical Oncology (ESMO) annual meeting in Madrid, Spain. This study evaluated 131 previously untreated patients with high-grade ovarian cancer. Blood samples were tested for germline (hereditary) BRCA mutations. Additionally, tumor samples were obtained from patients receiving surgery and were tested for both somatic (tumor) and germline BRCA mutations. The data analysis included 92 patients who completed testing for both germline and somatic mutations. The results show that the Tumor BRACAnalysis CDx test identified 28.3% of women with either germline or somatic BRCA 1/2 mutations. In contrast, blood germline testing only identified the 19.6% of patients with germline BRCA 1/2 mutations. The somatic mutations identified by Tumor BRACAnalysis CDx testing represent a 44% increase in the detection of cancer-causing BRCA mutations over germline testing. Myriad is actively collaborating with pharmaceutical companies to develop Tumor BRACAnalysis CDx as a companion diagnostic for use with certain PARP inhibitors, platinum-based drugs and other chemotherapeutic agents. In the United States, the testing will be done at the company's laboratory in Salt Lake City. In Europe, the test will be performed at the company's Munich laboratory. Prescribing physicians will receive Tumor BRACAnalysis CDx test results in approximately two weeks.

Myriad Genetics, Inc. Announces Amended and Restated By-Laws

On September 18, 2014, the board of directors of Myriad Genetics Inc. amended and restated the company's restated by-laws by adding a new Section 7 to Article VIII to designate Delaware as the sole and exclusive forum for specified legal actions, as detailed below, unless the company otherwise consents to a different forum.

Myriad Genetics Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 09:45 AM

Myriad Genetics Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-10-2014 09:45 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Mark Christopher Capone, President of Myriad Genetic Laboratories Inc.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYGN:US $38.89 USD +0.02

MYGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Drainage Systems Inc $20.89 USD -0.34
Bio-Reference Laboratories Inc $28.21 USD -0.18
Genomic Health Inc $29.26 USD -0.15
Imperial Innovations Group PLC 470.00 GBp 0.00
QIAGEN NV €18.09 EUR +0.01
View Industry Companies
 

Industry Analysis

MYGN

Industry Average

Valuation MYGN Industry Range
Price/Earnings 17.2x
Price/Sales 3.7x
Price/Book 4.0x
Price/Cash Flow 16.1x
TEV/Sales 3.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit www.myriad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.